Appointment

Date: 09.07.2026 To, To, BSE Limited National Stock Exchange of India Limited Listing Department Listing Department “Exchange Plaza,” Phiroze Jeejeebhoy Towers, C-1, Block G, Bandra – Kurla Complex, 25th Floor, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai - 400 001 Scrip Code: 544666 Sub.: Outcome of the Board Meeting held on July 09, 2026 (“Meeting”) Dear Sir Pursuant to Regulation 30 and other applicable Regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on today i.e. Thursday, 9th July, 2026 inter alia, consider and approved the following matters: Postal Ballot The Company will conduct postal ballot for seeking approval of the shareholders by way of Special Resolution for Variation in Objects of IPO. Intimation regarding the same shall be filed separately. Acquisition of Majority stake in Blue Tree Clinics LLC, UAE The Company shall acquire 51% stake in UAE based entity namely Blue Tree Clinics LLC vide a Share Purchase Agreement. The details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and SEBI Circular No. SEBI/HO/CFD/CFDPoD-2/CIR/P/2024/185 dated December 31, 2024 is enclosed as Annexure A. Appointment of Additional Director The Board has appointed Mr. (Dr) Paresh Dhoti (DIN: 11802188) as Additional- Non Executive- Independent Director with effect from 09.07.2026 The details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and SEBI Circular No. SEBI/HO/CFD/CFDPoD-2/CIR/P/2024/185 dated December 31, 2024 is enclosed as Annexure B. The Meeting commenced at 4:30 P.M. and concluded at 8 P.M. You are requested to kindly take the same on record. Thanking You. For Gujarat Kidney and Super Speciality Limited Pragnesh Bharpoda Managing Director DIN: 01033141 Date: 09.07.2026 To, To, BSE Limited National Stock Exchange of India Limited Listing Department Listing Department “Exchange Plaza,” Phiroze Jeejeebhoy Towers, C-1, Block G, Bandra – Kurla Complex, 25th Floor, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai - 400 001 Scrip Code: 544666 Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Acquisition of majority stake in Blue Tree Clinics LLC. Regulations, 2015, (‘SEBI Listing Regulations’), please be informed that Gujarat Kidney and Superspeciality Limited, has entered into a Stock Purchase Agreement with Blue Tree Clinics LLC (a ‘Target’ company in the Dubai), to acquire 51% stake, through a purchase of Equity Shares from existing shareholders. The target is a polyclinic duly licensed in Dubai, United Arab Emirates and is inter alia engaged in the business of registered activity as Plastic Surgery, Laser Cosmetic, General Dental Clinic and Chiropractic Centre. Details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, as amended, are enclosed as Attachment A. Kindly take the same on your records. Thanking you, For Gujarat Kidney and Super Speciality Limited Pragnesh Bharpoda Managing Director DIN: 01033141 ANNEXURE A Acquisition Majority stake in Blue Tree Clinics LLC, UAE Sr. No. Details to be provided Information 1 Name of the target entity, details Blue Tree Clinics LLC, a polyclinic duly in brief such as size, turnover etc. licensed in Dubai, United Arab Emirates and is inter alia engaged in the business of registered activity as Plastic Surgery, Laser Cosmetic, General Dental Clinic and Chiropractic Center. The Company has only equity shares. Presently there are 3 shareholders, 01 shareholder holding 91.866%, and 02 shareholders holding 8.114% During the FY 2025, the Gross Revenue of the target entity was 10,538,978 AED while the Net profit was 31,38,809 AED. 2 Whether the acquisition would Not Applicable as acquisition is not fall within related party falling within related party transaction. transactions and whether the promoter/ promoter group/ No promoter/promoter group/group group companies have any companies have any interest in the entity interest in the entity being in which shares are acquired. acquired? If yes, nature of the interest and details thereof and whether the same is done at 'arm's length' 3 Industry to which the entity being Medical Services acquired belongs 4 Objects and effects of acquisition Expansion of existing business of the (including but not limited to, Company in new geography and with a disclosure of reasons for set of services other than that of provided acquisition of target entity, if its by our company in India. business is outside the main line of business of the listed entity) 5 Brief details of governmental or No any regulatory approvals "required for the acquisition 6 Indicative time period for Consideration shall be paid in 2 completion of the acquisition tranches. Maximum time required 50 days. 7 Nature of Consideration whether Consideration in Cash Cash consideration or share swap and details of the same 8 Cost of Acquisition or the price at Rs 19,83,64,500/- payable in two which the shares are acquired tranches. 9 Percentage of shareholding Agreement to acquire 51% control acquired and /or number of shares acquired 10 Brief background about the entity Date of incorporation – 27/02/2012 acquired in terms of products/ line of business acquired, date of Country of incorporation and operations incorporation, history of last 3 – UAE years turnover, country in which the acquired entity has presence Last three years’ turnover – and any other significant FY 2023 – 11,249,500 AED information (in brief) FY 2024 – 9,068,150 AED FY 2025 - 10,538,978 AED This is for your information and records. For Gujarat Kidney and Super Speciality Limited Pragnesh Bharpoda Managing Director DIN: 01033141 Date: 09.07.2026 To, To, BSE Limited National Stock Exchange of India Limited Listing Department Listing Department “Exchange Plaza,” Phiroze Jeejeebhoy Towers, C-1, Block G, Bandra – Kurla Complex, 25th Floor, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai - 400 001 Scrip Code: 544666 Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Appointment of Additional Non-Executive Independent Director Dear Sir Pursuant to Regulation 30 of the Listing Regulations, it is hereby informed that based on the recommendation of the Nomination and Remuneration Committee of the Board, the Board of Directors of the Company in its Meeting today, 09-07-2026, has appointed Mr. Paresh Dhoti (DIN: 11802188) as an Additional Non-Executive Independent Director, not liable to retire by rotation, for a first term of five consecutive years, subject to the approval by the Members of the Company. The appointment shall be subject to the approval of Members at the next Annual General Meeting of the Company and compliance with Regulation 17(1C) and Regulation 25(2A) of the Listing Regulations and the relevant provisions of the Companies Act, 2013 shall be followed. Details with respect to the said appointment as required under Regulation 30(6) read with Para A (7) of Part - A of Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD PoD1/P/CIR/2023/123 dated 13th July 2023 are provided in Annexure B to this letter. Kindly take the same on your records. Thanking you, For Gujarat Kidney and Super Speciality Limited Pragnesh Bharpoda Managing Director DIN: 01033141 ANNEXURE B Details with respect to appointment of Additional Non-Executive Independent Director under Regulation 30(6) read with Para A (7) of Part A of Schedule III of the Listing Re [Showing first 8,000 characters — download PDF for full document]